Renal Denervation Two Late-Breaking Clinical Trials

SYMPLICITY HTN-3 Trial Objectives

Key Inclusion Criteria

Primary Efficacy End Points

Unique Qualities of SYMPLICITY HTN-3

Global SYMPLICITY Registry (cont)

Change in Ambulatory SBP for Global SYMPLICITY Registry and SYMPLICITY HTN-3 Patients

Issues to Address Following HTN-3

Response Rates* for Patients With Office SBP ≥160 mm Hg/Ambulatory SBP ≥135 mm Hg at Baseline†

SYMPLICITY HTN-3 Myths Dispelled

Results Prespecified Subgroup Analyses

Areas to Advance

Global SYMPLICITY Registry Number of Ablations per Patient

Pleiotropic Effects of Renal Denervation

Key Points and Moving Forward

Abbreviations

References